Chinese General Practice ›› 2024, Vol. 27 ›› Issue (21): 2572-2577.DOI: 10.12114/j.issn.1007-9572.2023.0769
Special Issue: 内分泌代谢性疾病最新文章合辑
• Original Research • Previous Articles Next Articles
Received:
2023-09-25
Revised:
2024-02-10
Published:
2024-07-20
Online:
2024-04-18
Contact:
LI Huiqin
通讯作者:
李惠琴
作者简介:
作者贡献:
周潇提出研究思路,设计研究方案,进行统计学分析,起草论文;周云婷、孔小岑、刘晓梅及袁璐负责开展研究,收集数据;荆亭、王蔚萍负责动态血糖监测安装;李惠琴指导研究开展,并进行论文质量控制及修订。
基金资助:
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2023.0769
项目 | 数值 |
---|---|
性别(男/女) | 60/28 |
年龄[M(P25,P75),岁] | 61.0(51.3,67.8) |
病程[M(P25,P75),年] | 5(2,10) |
Hb(g/L) | 146.61±27.19 |
BUN(mmol/L) | 5.19±1.14 |
Scr(μmol/L) | 66.47±13.60 |
ALT(U/L) | 25.14±9.87 |
AST(U/L) | 24.18±8.17 |
Alb(g/L) | 43.90±3.31 |
TP(g/L) | 71.28±4.06 |
UA(μmol/L) | 332.02±81.69 |
TC(mmol/L) | 4.76±1.54 |
TG[M(P25,P75),mmol/L] | 1.66(0.97,2.35) |
HDL(mmol/L) | 1.19±0.27 |
LDL(mmol/L) | 2.56±0.98 |
HbA1c(%) | 6.85±0.97 |
Table 1 Baseline clinical characteristics
项目 | 数值 |
---|---|
性别(男/女) | 60/28 |
年龄[M(P25,P75),岁] | 61.0(51.3,67.8) |
病程[M(P25,P75),年] | 5(2,10) |
Hb(g/L) | 146.61±27.19 |
BUN(mmol/L) | 5.19±1.14 |
Scr(μmol/L) | 66.47±13.60 |
ALT(U/L) | 25.14±9.87 |
AST(U/L) | 24.18±8.17 |
Alb(g/L) | 43.90±3.31 |
TP(g/L) | 71.28±4.06 |
UA(μmol/L) | 332.02±81.69 |
TC(mmol/L) | 4.76±1.54 |
TG[M(P25,P75),mmol/L] | 1.66(0.97,2.35) |
HDL(mmol/L) | 1.19±0.27 |
LDL(mmol/L) | 2.56±0.98 |
HbA1c(%) | 6.85±0.97 |
时间 | 1 h | 2 h | 3 h | 4 h | 5 h | 6 h | 7 h | 8 h | 9 h | 10 h | 11 h | 12 h |
---|---|---|---|---|---|---|---|---|---|---|---|---|
第2天血糖 | 7.41±2.28 | 7.01±2.14 | 6.87±2.00 | 6.84±1.91 | 6.87±1.91 | 7.02±1.90 | 7.42±2.00 | 8.19±2.20 | 9.29±2.31 | 9.79±2.75 | 9.32±2.99 | 8.85±3.23 |
第5天血糖 | 6.94±1.66 | 6.68±1.51 | 6.55±1.46 | 6.48±1.54 | 6.59±1.57 | 6.76±1.60 | 7.02±1.63 | 7.63±1.84 | 8.90±2.43 | 9.19±2.82 | 8.40±2.72 | 7.67±2.40 |
t配对值 | 2.37 | 1.87 | 1.75 | 1.93 | 1.74 | 1.85 | 3.05 | 3.04 | 1.62 | 2.23 | 3.49 | 3.88 |
P值 | 0.020 | 0.065 | 0.084 | 0.057 | 0.086 | 0.068 | 0.003 | 0.003 | 0.110 | 0.028 | 0.001 | <0.001 |
时间 | 13 h | 14 h | 15 h | 16 h | 17 h | 18 h | 19 h | 20 h | 21 h | 22 h | 23 h | 24 h |
第2天血糖 | 8.87±3.17 | 9.52±2.89 | 9.39±2.83 | 8.98±2.76 | 8.63±2.53 | 8.32±2.61 | 8.52±2.57 | 8.96±2.67 | 9.22±3.00 | 8.83±3.03 | 8.33±2.77 | 7.72±2.43 |
第5天血糖 | 7.83±2.33 | 8.66±2.57 | 8.83±2.70 | 8.72±2.78 | 8.36±2.76 | 7.95±2.57 | 7.89±2.37 | 8.37±2.18 | 8.75±2.18 | 8.51±2.31 | 8.12±2.37 | 7.66±2.10 |
t配对值 | 3.72 | 3.11 | 2.00 | 1.02 | 1.11 | 1.49 | 2.94 | 2.72 | 1.73 | 1.20 | 0.85 | 0.28 |
P值 | <0.001 | 0.003 | 0.049 | 0.311 | 0.270 | 0.140 | 0.004 | 0.008 | 0.086 | 0.233 | 0.397 | 0.778 |
Table 2 Comparison of glycemic profile before and after intervention
时间 | 1 h | 2 h | 3 h | 4 h | 5 h | 6 h | 7 h | 8 h | 9 h | 10 h | 11 h | 12 h |
---|---|---|---|---|---|---|---|---|---|---|---|---|
第2天血糖 | 7.41±2.28 | 7.01±2.14 | 6.87±2.00 | 6.84±1.91 | 6.87±1.91 | 7.02±1.90 | 7.42±2.00 | 8.19±2.20 | 9.29±2.31 | 9.79±2.75 | 9.32±2.99 | 8.85±3.23 |
第5天血糖 | 6.94±1.66 | 6.68±1.51 | 6.55±1.46 | 6.48±1.54 | 6.59±1.57 | 6.76±1.60 | 7.02±1.63 | 7.63±1.84 | 8.90±2.43 | 9.19±2.82 | 8.40±2.72 | 7.67±2.40 |
t配对值 | 2.37 | 1.87 | 1.75 | 1.93 | 1.74 | 1.85 | 3.05 | 3.04 | 1.62 | 2.23 | 3.49 | 3.88 |
P值 | 0.020 | 0.065 | 0.084 | 0.057 | 0.086 | 0.068 | 0.003 | 0.003 | 0.110 | 0.028 | 0.001 | <0.001 |
时间 | 13 h | 14 h | 15 h | 16 h | 17 h | 18 h | 19 h | 20 h | 21 h | 22 h | 23 h | 24 h |
第2天血糖 | 8.87±3.17 | 9.52±2.89 | 9.39±2.83 | 8.98±2.76 | 8.63±2.53 | 8.32±2.61 | 8.52±2.57 | 8.96±2.67 | 9.22±3.00 | 8.83±3.03 | 8.33±2.77 | 7.72±2.43 |
第5天血糖 | 7.83±2.33 | 8.66±2.57 | 8.83±2.70 | 8.72±2.78 | 8.36±2.76 | 7.95±2.57 | 7.89±2.37 | 8.37±2.18 | 8.75±2.18 | 8.51±2.31 | 8.12±2.37 | 7.66±2.10 |
t配对值 | 3.72 | 3.11 | 2.00 | 1.02 | 1.11 | 1.49 | 2.94 | 2.72 | 1.73 | 1.20 | 0.85 | 0.28 |
P值 | <0.001 | 0.003 | 0.049 | 0.311 | 0.270 | 0.140 | 0.004 | 0.008 | 0.086 | 0.233 | 0.397 | 0.778 |
项目 | MBG(mmol/L) | SD(mmol/L) | MAGE(mmol/L) | TIR(%) | TAR[M(P25,P75),%] | TBR[M(P25,P75),%] |
---|---|---|---|---|---|---|
第2天 | 8.34±1.97 | 1.80±0.80 | 4.53±2.25 | 78.21±24.64 | 9.90(3.82,31.86) | 0(0,0) |
第5天 | 7.85±1.65 | 1.62±0.74 | 3.80±1.80 | 84.28±21.87 | 5.38 (0,22.83) | 0(0,0) |
t配对(Z配对)值 | 4.07 | 2.79 | 3.24 | 3.41 | -3.83a | -0.73a |
P值 | <0.001 | 0.006 | 0.002 | 0.001 | <0.001 | 0.463 |
Table 3 Comparison of CGM parameters before and after intervention
项目 | MBG(mmol/L) | SD(mmol/L) | MAGE(mmol/L) | TIR(%) | TAR[M(P25,P75),%] | TBR[M(P25,P75),%] |
---|---|---|---|---|---|---|
第2天 | 8.34±1.97 | 1.80±0.80 | 4.53±2.25 | 78.21±24.64 | 9.90(3.82,31.86) | 0(0,0) |
第5天 | 7.85±1.65 | 1.62±0.74 | 3.80±1.80 | 84.28±21.87 | 5.38 (0,22.83) | 0(0,0) |
t配对(Z配对)值 | 4.07 | 2.79 | 3.24 | 3.41 | -3.83a | -0.73a |
P值 | <0.001 | 0.006 | 0.002 | 0.001 | <0.001 | 0.463 |
时间 | 早餐前1 h | 早餐后2 h | 午餐前1 h | 午餐后2 h | 晚餐前1 h | 晚餐后2 h |
---|---|---|---|---|---|---|
第2天 | 7.42±2.00 | 8.74±2.13 | 9.32±2.99 | 8.86±3.10 | 8.63±2.53 | 8.74±2.50 |
第5天 | 7.02±1.63 | 8.27±2.01 | 8.40±2.72 | 7.75±2.24 | 8.36±2.76 | 7.92±2.37 |
t配对值 | 3.05 | 2.44 | 3.49 | 4.02 | 1.11 | 3.86 |
P值 | 0.003 | 0.017 | 0.001 | <0.001 | 0.270 | <0.001 |
Table 4 Comparison of blood glucose levels before and after intervention
时间 | 早餐前1 h | 早餐后2 h | 午餐前1 h | 午餐后2 h | 晚餐前1 h | 晚餐后2 h |
---|---|---|---|---|---|---|
第2天 | 7.42±2.00 | 8.74±2.13 | 9.32±2.99 | 8.86±3.10 | 8.63±2.53 | 8.74±2.50 |
第5天 | 7.02±1.63 | 8.27±2.01 | 8.40±2.72 | 7.75±2.24 | 8.36±2.76 | 7.92±2.37 |
t配对值 | 3.05 | 2.44 | 3.49 | 4.02 | 1.11 | 3.86 |
P值 | 0.003 | 0.017 | 0.001 | <0.001 | 0.270 | <0.001 |
组别 | 例数 | MBG(mmol/L) | SD | MAGE(mmol/L) | TIR(%) | TAR[M(P25,P75),%] | TBR[M(P25,P75),%] | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
第2天 | 第5天 | 第2天 | 第5天 | 第2天 | 第5天 | 第2天 | 第5天 | 第2天 | 第5天 | 第2天 | 第5天 | ||
病程<10年组 | 62 | 8.27±2.11 | 7.82±1.89a | 1.78±0.81 | 1.58±0.77a | 4.47±2.01 | 3.75±1.79a | 77.88±25.71 | 83.81±24.69a | 9.38(2.26,37.07) | 4.69(0,14.67) a | 0(0,0) | 0(0,0) |
病程≥10年组 | 26 | 8.51±1.60 | 7.95±0.90a | 1.84±0.79 | 1.72±0.66 | 4.67±2.79 | 3.92±1.83 | 78.99±22.35 | 85.38±13.26 | 14.76(5.99,29.25) | 12.50(0,23.87) | 0(0,0) | 0(0,0) |
t(Z)值 | -0.53 | -0.44 | -0.32 | -0.83 | -0.37 | -0.41 | -0.19 | -0.39 | 0.07b | 0.44b | 1.63b | -0.54b | |
P值 | 0.600 | 0.662 | 0.751 | 0.408 | 0.711 | 0.685 | 0.849 | 0.699 | 0.944 | 0.658 | 0.108 | 0.592 |
Table 5 Comparison of CGM parameters before and after treatment in diabetes of different course groups
组别 | 例数 | MBG(mmol/L) | SD | MAGE(mmol/L) | TIR(%) | TAR[M(P25,P75),%] | TBR[M(P25,P75),%] | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
第2天 | 第5天 | 第2天 | 第5天 | 第2天 | 第5天 | 第2天 | 第5天 | 第2天 | 第5天 | 第2天 | 第5天 | ||
病程<10年组 | 62 | 8.27±2.11 | 7.82±1.89a | 1.78±0.81 | 1.58±0.77a | 4.47±2.01 | 3.75±1.79a | 77.88±25.71 | 83.81±24.69a | 9.38(2.26,37.07) | 4.69(0,14.67) a | 0(0,0) | 0(0,0) |
病程≥10年组 | 26 | 8.51±1.60 | 7.95±0.90a | 1.84±0.79 | 1.72±0.66 | 4.67±2.79 | 3.92±1.83 | 78.99±22.35 | 85.38±13.26 | 14.76(5.99,29.25) | 12.50(0,23.87) | 0(0,0) | 0(0,0) |
t(Z)值 | -0.53 | -0.44 | -0.32 | -0.83 | -0.37 | -0.41 | -0.19 | -0.39 | 0.07b | 0.44b | 1.63b | -0.54b | |
P值 | 0.600 | 0.662 | 0.751 | 0.408 | 0.711 | 0.685 | 0.849 | 0.699 | 0.944 | 0.658 | 0.108 | 0.592 |
组别 | 例数 | MBG(mmol/L) | SD | MAGE(mmol/L) | TIR(%) | TAR[M(P25,P75),%] | TBR[M(P25,P75),%] | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
第2天 | 第5天 | 第2天 | 第5天 | 第2天 | 第5天 | 第2天 | 第5天 | 第2天 | 第5天 | 第2天 | 第5天 | ||
年龄<65岁组 | 55 | 8.42±2.10 | 7.94±1.87a | 1.78±0.82 | 1.55±0.62a | 4.54±2.22 | 3.78±1.87a | 77.40±26.92 | 83.06±24.56a | 9.38(2.43,38.89) | 5.56(0,22.92)a | 0(0,0) | 0(0,0) |
年龄<65岁组 | 33 | 8.20±1.76 | 7.72±1.21a | 1.83±0.78 | 1.74±0.90 | 4.52±2.34 | 3.85±1.70 | 79.57±20.60 | 86.30±16.62a | 10.76(5.56,30.90) | 5.21(0,24.65)a | 0(0,0) | 0(0,0) |
t(Z)值 | 0.51 | 0.60 | -0.27 | -1.21 | 0.05 | -0.17 | -0.40 | -0.67 | 0.55b | 0.64b | -1.30b | 0.10b | |
P值 | 0.615 | 0.548 | 0.788 | 0.231 | 0.961 | 0.866 | 0.692 | 0.504 | 0.587 | 0.526 | 0.204 | 0.919 |
Table 6 Comparison of CGM parameters before and after treatment in patients of different age groups
组别 | 例数 | MBG(mmol/L) | SD | MAGE(mmol/L) | TIR(%) | TAR[M(P25,P75),%] | TBR[M(P25,P75),%] | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
第2天 | 第5天 | 第2天 | 第5天 | 第2天 | 第5天 | 第2天 | 第5天 | 第2天 | 第5天 | 第2天 | 第5天 | ||
年龄<65岁组 | 55 | 8.42±2.10 | 7.94±1.87a | 1.78±0.82 | 1.55±0.62a | 4.54±2.22 | 3.78±1.87a | 77.40±26.92 | 83.06±24.56a | 9.38(2.43,38.89) | 5.56(0,22.92)a | 0(0,0) | 0(0,0) |
年龄<65岁组 | 33 | 8.20±1.76 | 7.72±1.21a | 1.83±0.78 | 1.74±0.90 | 4.52±2.34 | 3.85±1.70 | 79.57±20.60 | 86.30±16.62a | 10.76(5.56,30.90) | 5.21(0,24.65)a | 0(0,0) | 0(0,0) |
t(Z)值 | 0.51 | 0.60 | -0.27 | -1.21 | 0.05 | -0.17 | -0.40 | -0.67 | 0.55b | 0.64b | -1.30b | 0.10b | |
P值 | 0.615 | 0.548 | 0.788 | 0.231 | 0.961 | 0.866 | 0.692 | 0.504 | 0.587 | 0.526 | 0.204 | 0.919 |
[1] |
|
[2] |
|
[3] |
UK Prospective Diabetes Study(UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes(UKPDS 34)[J]. Lancet,1998,352(9131):854-865.
|
[4] |
|
[5] |
|
[6] |
中华医学会内分泌学分会. 中国2型糖尿病合并肥胖综合管理专家共识[J]. 中华糖尿病杂志,2016,8(11):662-666. DOI:10.3760/cma.j.issn.1674-5809.2016.11.006.
|
[7] |
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华内分泌代谢杂志,2021,37(4):311-398. DOI:10.3760/cma.j.cn311282-20210304-00142.
|
[8] |
|
[9] | |
[10] |
|
[11] |
|
[12] |
中华医学会糖尿病学分会. 中国血糖监测临床应用指南(2011年版)续[J]. 中华医学信息导报,2011,26(9):19-20.
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
赵晓龙,吴宸炜. 扫描式持续葡萄糖监测基层临床应用指导[J]. 中华糖尿病杂志,2023,15(4):377-382. DOI:10.3760/cma.j.cn115791-20221019-00614.
|
[18] |
蔡玉立,易波,陈小琳,等. 动态血糖监测技术与临床研究进展[J]. 中国糖尿病杂志,2021,29(12):933-940. DOI:10.3969/j.issn.1006-6187.2021.12.010.
|
[19] |
金百翰,宋敬云,谢俊豪,等. 门诊2型糖尿病患者行动态血糖监测的临床价值及影响因素[J]. 中国糖尿病杂志,2019,27(1):11-15. DOI:10.3969/j.issn.1006-6187.2019.01.004.
|
[20] |
|
[21] |
|
[22] |
|
[23] |
|
[24] |
|
[25] |
国家老年医学中心,中华医学会老年医学分会,中国老年保健协会糖尿病专业委员会. 中国老年糖尿病诊疗指南(2021年版)[J]. 中华糖尿病杂志,2021,13(1):14-46. DOI:10.3760/cma.j.cn115791-20201209-00707.
|
[26] |
|
[1] | LI Xiaoze, SUN Guoqiang, SHEN Qiang, SONG Yan, WANG Hufeng. Effectiveness of Individualized Health Education Interventions on Middle-aged and Elderly Patients with Chronic Diseases in the Community: a Cluster Randomized Controlled Trial [J]. Chinese General Practice, 2025, 28(11): 1320-1328. |
[2] | HE Runxian, LU Wenjie, JIANG Haotian, HU Yan, LIU Qing, GAO Ye, LIU Xu. Exploration and Research on Innovative Models for Alleviating Health Poverty in Western China's Child: a Case Study Based on the "Guguding" Medical Science Popularization and Training Program [J]. Chinese General Practice, 2025, 28(11): 1417-1420. |
[3] | YAN Wenxin, HU Jian, ZENG Huatang, LIU Min, LIANG Wannian. The Application of Large Language Models in Primary Healthcare Services and the Challenges [J]. Chinese General Practice, 2025, 28(01): 1-6. |
[4] | LIU Yu, ZHAO Fang, WANG Li, LI Caihong, LIN Keke, BAI Xiaoyan, WU Shishi, ZHANG Ruiting, WANG Jing. The Effect of Social Network-based Health Education on Self-management of Older Adults with Chronic Diseases in Community [J]. Chinese General Practice, 2024, 27(34): 4295-4301. |
[5] | ZHAO Yuling, GU Zhengping, ZHANG Xueying. Progress and Challenges in the Integration of Treatment and Prevention of Chronic Non-communicable Diseases [J]. Chinese General Practice, 2024, 27(31): 3953-3957. |
[6] | ZOU Hai, CHEN Zhenyao, HE Xigan, MOU Xiaozhou, ZHANG Zhongwei, ZHU Biao, WEI Peng, LIU Jing. Exploration and Practice of an Innovative Model of Community-based Popularization of Knowledge in Critical Care Medicine [J]. Chinese General Practice, 2024, 27(24): 3051-3056. |
[7] | DAI Zhenwei, ZHANG Ling, ZHANG Haoran, XIAO Weijun, WANG Hao, HUANG Yiman, JING Shu, CHEN Xu, FU Jiaqi, WU Yijin, GAO Lei, SU Xiaoyou. Influencing Factors of Blood Glucose Monitoring in Middle-aged and Elderly Patients with Type-2 Diabetes Mellitus in Rural Areas [J]. Chinese General Practice, 2024, 27(10): 1194-1200. |
[8] | GAO Yuan, ZHOU Min, QIN Manfen, XU Xuan, YANG Liping, FU Yahong, HUANG Ying, WANG Wei. Effects of Health Coaching Combined with Wearable Devices on Glucose and Lipid Metabolism and Self-management Behavior in Patients with Type 2 Diabetes Mellitus [J]. Chinese General Practice, 2024, 27(08): 908-914. |
[9] | CHU Xiaojing, LI Jun, FU Yanqin, LIU Danqing, LIU Aiping, ZHANG Yuanyuan. Effect of Human Body Composition and Serum Biochemical Indicators on the Accuracy of Flash Glucose Monitoring System [J]. Chinese General Practice, 2023, 26(35): 4433-4438. |
[10] | ZHENG Siting, HE Chunyu, ZHOU Jun, KONG Ye, YANG Xinyao, ZHOU Haiying, WEI Xiaofei. Summary of Best Evidence for Self-Management of Patients with Motor Dysfunction after Stroke [J]. Chinese General Practice, 2023, 26(26): 3230-3237. |
[11] | FANG Fusheng, LIU Xingyu, YAN Shuangtong, WANG Ning, LI Chunlin, TIAN Hui. Relationship between Time in Range and Long-term HbA1c Glycemic Variability in Elderly Male Patients with Type 2 Diabetes [J]. Chinese General Practice, 2023, 26(16): 1979-1983. |
[12] | SHU Tao, GUO Zheng, WANG Fei, CHEN Shuyan. Analysis of the Correlation between Time in Range and Diabetic Kidney Disease [J]. Chinese General Practice, 2023, 26(15): 1873-1879. |
[13] | HUANG Mengjie, ZENG Leixiao, GE Pu, MIN Hewei, HUANG Xincheng, WANG Yujia, WU Yibo. Perceived Needs of Health Education and Associated Factors among Community-dwelling Residents [J]. Chinese General Practice, 2023, 26(04): 426-433. |
[14] | CHEN Junjian, FAN Guanhua. Prevalence and Associated Factors of Effective Self-monitoring of Blood Glucose Frequency in Community-living People with Glycemic Management [J]. Chinese General Practice, 2022, 25(34): 4298-4303. |
[15] | Zimo PAN, Lin CHU, Lingxia CHEN, Jingtong WANG. Association of Metrics Derived from a Flash Glucose Monitoring System with Urine Albumin-to-creatinine Ratio in T2DM Patients [J]. Chinese General Practice, 2022, 25(23): 2856-2863. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||